Univ of Iowa Research Team Finds New Genetic Cause of Retinitis Pigmentosa

August 20, 2011

Combining the expertise of several different labs, University of Iowa researchers have found a new genetic cause of the blinding eye disease retinitis pigmentosa (RP) and, in the process, discovered an entirely new version of the message that codes for the affected protein.

The study, which was published online August 8 in the Proceedings of the National Academy of Sciences (PNAS) Early Edition, suggests that the mutation may be a significant cause of RP in people of Jewish descent. The findings also lay the groundwork for developing prevention and treatment for this form of RP using a combination of genetic testing, gene therapy and cell replacement approaches.

Using the latest DNA sequencing techniques to analyze the protein-coding regions of a single RP patient’s genome, the researchers found a mutation in a gene called MAK (male germ cell associated kinase). This gene had not previously been associated with eye disease in humans. However, examining tissue from donated eyes showed that MAK protein was located in the parts of the retina that are affected by the disease.

The researchers then generated induced pluripotent stem cells (iPSCs) from the patient’s own skin cells and coaxed these immature cells to develop into retinal tissue. Analyzing this tissue showed that the gene mutation caused the loss of the MAK protein in the retina.

“These new technologies have greatly enhanced our ability to find and validate disease-causing mutations, which is critical to our ability to progress to the next step of actually treating diseases like RP,” said Budd Tucker, PhD, UI assistant professor of ophthalmology and visual science and lead study author.

Based on the new work, the UI team hopes to explore gene therapy and cell replacement strategies as potential therapies for this form of RP.

http://www.uihealthcare.org/Newsarticle.aspx?id=225780

 


Stem Cell Info Blog

August 10, 2011

Amy Evan runs a Biology blog. In it she had a n interesting article on Stem Cell research.

She has gathered 15 interesting facts you may not know about stem cell research. They include the past, current state, and even future of stem cell research and are by journalists, scientists, doctors, and more.

An example: The Blind Might be Able to See
Could Stevie Wonder actually get to see for the first time? A small biotech firm in California hopes the answer is “yes.” Two patients suffering from macular degeneration, or a form of blindness, volunteered to have lab grown retinal cells implanted.

For complete info, see:

http://onlinebiologydegree.org/2011/15-interesting-facts-you-may-not-know-about-stem-cell-research/


Stem Cell Trials To Begin For Stargardt’s Treatment

June 20, 2011

Advanced Cell Technology Inc. (ACT) announced Thursday the enrollment of the patients in the trials for Stargardt’s Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (Dry AMD). The patients were enrolled at the Jules Stein Eye Institute at the University of California, Los Angeles.

ACT won approval by the US Food and Drug Administration in January to use human embryonic stem cells for treating macular degeneration, a common cause of vision loss. That followed FDA approval in November for scientists to test the stem cells to treat people with Stargardt’s Macular Dystrophy. The new trials will test the safety and tolerability of retinal pigment epithelial, or RPE cells, which ACT makes from the human embryonic stem cells.

Animal studies have reportedly shown that injecting fresh RPE cells into the eye could bring about a substantial improvement in eyesight. In other studies, scientists said mice with eye disease recovered near-normal vision after receiving the therapy.

In addition to the Jules Stein Eye Institute at UCLA, the Casey Eye Institute (CEI) at Oregon Health & Science University (OHSU) in Portland, OR, is also open for enrollment of patients with SMD.

As additional sites are ready to enroll patients with SMD and dry AMD, they will be listed on the Clinical Trials page on ACT’s Web site and at http://www.clinicaltrials.gov.

http://www.redorbit.com/news/health/2066060/stem_cell_trials_to_begin_for_blindness_treatment/


Retinitis Pigmentosa Reference Page

June 13, 2011

The first sign of retinitis pigmentosa is usually a loss of night vision, which becomes apparent in childhood. Problems with night vision can make it difficult to navigate in low light. Later, the disease causes blind spots to develop in the side (peripheral) vision. Over time, these blind spots merge to produce tunnel vision. The disease progresses over years or decades to affect central vision, which is needed for detailed tasks such as reading, driving, and recognizing faces. In adulthood, many people with retinitis pigmentosa become legally blind.

The Genetics Home Reference Page of the US Natl Library of Medicine has extensive info about Retinitis Pigmentosa, including possible treatment.

http://ghr.nlm.nih.gov/condition/retinitis-pigmentosa

 


Scientists create replacements for dead Retinal Cells.

May 30, 2011

Macular Degeneration and Retinitis Pigmentosa lead to the death of the photo-receptor cells (the rods and the cones) in the retina. Scientists at the MIT Media Lab and at EOS Neuroscience are working on a replacement for dead photo-receptor cells.

Light Photocells are created by using the DNA from photosensitive algae implanted in bi-polar retinal cells. The bi-polar cells normally amplify the signal from the rods and cones and pass the nerve signal to the ganglions which then feed the optic nerve. The implanted DNA causes the bi-polar cells to become photo-receptors, thus restoring sight.

Synthetic Neuro-Biology Group at the MIT Media Lab

http://syntheticneurobiology.org/

Video: http://www.ted.com/talks/ed_boyden.html

Illustration of Photo-receptors, bipolar conductors and ganglion

http://spie.org/x32352.xml

Light Photocells created by using algae to implant light sensitivity in bi-polar retinal cells.

http://eosneuroscience.com/news/detail/?id=21


Best Blogs for Following Stem Cell Research

April 17, 2011

Roxanne McAnn of the nursingdegree.net/blog has called our attention to a recent article they published.

Stem cell research has been a contentious issue in both the scientific and political spheres for quite some years. Despite the ongoing battle between those who support and those who oppose the research and treatments, new discoveries and advances in the field are being made all the time. Whether you’re pursuing a career in medicine or science, or seeking recent info,  if you’d like to keep up with these advances, then blogs on the issue are one of the best tools out there. Here, you’ll find a collection of blogs that provide all the information you’ll need to stay on top of the latest in stem cell discoveries.

Go here for details:

Use “Search” box on each blog to find details on AMD, RP, Stargardt’s etc.

http://www.nursingdegree.net/blog/750/25-best-blogs-for-following-stem-cell-research/


Retinal Cells made from Stem Cells

March 28, 2011

Scientists at Georgetown Univ. have successfully fashioned adult stem cells into the kind of eye cells that fall victim to the onset of age-related macular degeneration, or AMD.

But the researchers, from the Georgetown University Medical Center in Washington, D.C., stress that this was a preliminary move toward that goal, achieved solely in a laboratory setting. They say that numerous complex obstacles must be tackled before such newly created cells could be transplanted into diseased eyes.

http://www.businessweek.com/lifestyle/content/healthday/651135.html

 


Macular Degeneration Stem Cell Treatment

January 24, 2011

Did you know that stem cells are currently being used for macular degeneration treatment?

However, these stem cells are not embryonic, but rather autologous.

There are many sources of stem cells, but one common source that is used for many cancer patients needing bone marrow transplants, is a patient’s own bone marrow. These immature stem cells have the ability to develop into other specialized cells.

The X-Cell Center in Germany is one such center. In the United States, Dr. Edward Kondrot in Cave Creek, Arizona has begun using stem cell therapy as well.

On January 3, 2011, Advanced Cell Technology announced that the United States FDA approved their application to treatmacular degeneration stem cellsdry age-related macular degeneration (AMD)using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells.

Sites currently under consideration are the Jules Stein Eye Institute at UCLA, and the Ophthalmology Department at Stanford University School of Medicine.

http://www.webrn-maculardegeneration.com/macular-degeneration-and-stem-cells.html

 


Stem Cell Therapy for Recovering Sight

January 17, 2011

UC Irvine assistant professor of ophthalmology is on the road to success with a stem cell-based therapy for retinitis pigmentosa, a genetic eye condition that affects millions of Americans and people worldwide.

For the past 25 years, Dr. Henry Klassen has been focusing on regenerating damaged retinal tissue so that people suffering from retinitis pigmentosa and macular degeneration could regain their sight.

Also, the doctor believes that “the eye is an important proving ground for stem cell-based therapies.”

In his research, Dr Klassen is discovering new ways that stem cells can be used to fix the retina, which is actually the only part of the body’s intricate central nervous system that can be seen without surgery.

By doing so, Klassen is gathering information about stem cells that goes beyond eye disease.

http://news.softpedia.com/news/Stem-Cells-for-Recovering-Sight-177548.shtml


ACT gets FDA Approval for AMD Treatment Trial

January 13, 2011

Advanced Cell Technology, Inc. (“ACT“), a leader in the field of regenerative medicine, announced today that the US Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to treat Dry Age-Related Macular Degeneration (AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). ACT is now permitted to initiate a Phase I/II multicenter clinical trial to treat patients with Dry AMD, the most common form of macular degenerationin the world. There are currently no treatments available for this prevalent disease of an aging global population. Dry AMD, representing a substantial global market opportunity and afflicts between 10-15 million Americans.

http://www.news-medical.net/news/20110103/FDA-clears-ACTs-IND-to-treat-AMD-using-hESC-derived-RPE-cells.aspx

http://www.masshightech.com/stories/2011/01/03/daily8-ACTs-Dry-AMD-therapy-boosted-by-25M-funding-FDA-clearance.html

 


Follow

Get every new post delivered to your Inbox.